A comparison of short-term efficacy and safety of small-caliber polyvinyl alcohol microsphere-based versus conventional TACE for unresectable hepatocellular carcinoma

LI Shaowei; LI Jianguo; WANG Junchen; WANG Shuxia; MA Guoqiang; LI Yumin; GUO Li; HU Wei

doi:10.6039/j.issn.1001-0408.2026.20.17

您当前的位置：

首页 >

文章列表页 >

A comparison of short-term efficacy and safety of small-caliber polyvinyl alcohol microsphere-based versus conventional TACE for unresectable hepatocellular carcinoma

更新时间：2026-10-29

- A comparison of short-term efficacy and safety of small-caliber polyvinyl alcohol microsphere-based versus conventional TACE for unresectable hepatocellular carcinoma
- ZHONGGUO YAOFANG Vol. 37, Issue 20, Pages: 2732-2738(2026)
- 作者机构：
  
  1.甘肃省第二人民医院（西北民族大学附属医院）介入与血管外科，兰州;730030
  2.甘肃省第二人民医院（西北民族大学附属医院）肿瘤内科，兰州　730030
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2026.20.17
  CLC： R735.7;R969.4
- Received：04 June 2026，
  
  Revised：2026-10-15，
  
  Accepted：16 October 2026，
  
  Published：30 October 2026
- 稿件说明：
移动端阅览
李少伟,李建国,王骏臣,等.小粒径聚乙烯醇微球与传统TACE治疗不可切除肝细胞癌的近期疗效及安全性比较 [J].中国药房,2026,37(20):2732-2738.

LI Shaowei,LI Jianguo,WANG Junchen,et al.A comparison of short-term efficacy and safety of small-caliber polyvinyl alcohol microsphere-based versus conventional TACE for unresectable hepatocellular carcinoma[J].ZHONGGUO YAOFANG,2026,37(20):2732-2738.
李少伟,李建国,王骏臣,等.小粒径聚乙烯醇微球与传统TACE治疗不可切除肝细胞癌的近期疗效及安全性比较 [J].中国药房,2026,37(20):2732-2738. DOI： 10.6039/j.issn.1001-0408.2026.20.17.

LI Shaowei,LI Jianguo,WANG Junchen,et al.A comparison of short-term efficacy and safety of small-caliber polyvinyl alcohol microsphere-based versus conventional TACE for unresectable hepatocellular carcinoma[J].ZHONGGUO YAOFANG,2026,37(20):2732-2738. DOI： 10.6039/j.issn.1001-0408.2026.20.17.

摘要

目的

比较小粒径聚乙烯醇（PVA）微球经导管动脉化疗栓塞术（TACE）与传统碘油乳剂TACE治疗不可切除肝细胞癌（HCC）的近期疗效及安全性。

方法

回顾性纳入2024年6月1日至2025年6月30日在甘肃省第二人民医院（西北民族大学附属医院）接受TACE治疗的146例不可切除HCC患者的临床资料，根据TACE方案不同将其分为对照组（传统碘油乳剂TACE治疗，79例）和观察组（小粒径PVA微球TACE治疗，67例）。采用1∶1倾向评分匹配（PSM），以匹配队列（每组各62例）为主要分析人群，比较其治疗后1、3个月时的客观缓解率（ORR）和疾病控制率（DCR），治疗前及治疗后1、3个月时的肿瘤标志物（甲胎蛋白、甲胎蛋白异质体L3、维生素K缺乏或拮抗剂Ⅱ诱导蛋白）水平，不良事件发生情况，以及其无进展生存期（PFS）和总生存期（OS）。以原始队列为对象，进行敏感性分析和交互作用分析。

结果

PSM后，观察组患者治疗后1、3个月时的ORR均为59.7%，DCR分别为91.9%、93.5%，均显著高于对照组的ORR（41.9%、38.7%）和DCR（77.4%、75.8%）（

＜0.05）；两组患者治疗后1、3个月时的肿瘤标志物水平均较同组治疗前显著降低，且观察组显著低于同期对照组（

＜0.05）；两组患者不良事件总发生率及≥3级不良事件发生率比较，差异均无统计学意义（

＞0.05）。对照组、观察组患者的中位PFS分别为10.6、14.3个月，组间比较差异无统计学意义（风险比为0.69，95%置信区间为0.44～1.09，

＝0.111）；两组分别有8、9例患者死亡，均未达到中位OS，12个月的OS率分别为88.8%、87.3%，组间比较差异亦无统计学意义（风险比为0.88，95%置信区间为0.35～2.24，

＝0.790）。原始队列经混杂因素校正后，观察组患者治疗后3个月时的ORR仍显著高于对照组（校正后比值比为2.67，95%置信区间为1.28～5.56，

P＝

0.009），且治疗方式与巴塞罗那临床肝癌分期的交互作用对患者治疗后3个月时ORR的影响无统计学意义（

＝0.391）。

结论

对于不可切除HCC患者，与传统碘油乳剂TACE相比，小粒径PVA微球TACE在近期影像学缓解、肿瘤标志物改善方面的效果更优，且两种方案的安全性相当。

Abstract

OBJECTIVE

To compare the short-term efficacy and safety of small-caliber polyvinyl alcohol （PVA） microsphere-based transcatheter arterial chemoembolization （TACE） versus conventional iodized oil emulsion-based TACE in the treatment of unresectable hepatocellular carcinoma （HCC）.

METHODS

Clinical data of 146 patients with unresectable HCC who underwent TACE at Gansu Provincial Second People’s Hospital （Affiliated Hospital of Northwest Minzu University） from June 1， 2024， to June 30， 2025， were retrospectively collected. According to the treatment strategy， the patients were divided into the control group （conventional iodized oil emulsion-based TACE，

＝79） and the observation group （small-caliber PVA microsphere-based TACE，

＝67）. One-to-one propensity score matching （PSM） was performed， and the matched cohort （62 patients in each group） was used for the primary analysis. The objective response rate （ORR） and disease control rate （DCR） at 1 and 3 months post-treatment， serum levels of tumor markers （alpha-fetoprotein， alpha-fetoprotein lectin-binding fraction L3， and protein induced by vitamin K absence or antagonist-Ⅱ） before treatment and at 1 and 3 months post-treatment， the occurrence of adverse events， progression-free survival （PFS）， and overall survival （OS） were compared between the two groups. Sensitivity and interaction analyses were also performed.

RESULTS

After PSM， the ORRs in the observation group at 1 and 3 months post-treatment were both 59.7%， and the DCRs were 91.9% and 93.5%， respectively， significantly higher than those in the control group （ORRs： 41.9% and 38.7%； DCRs： 77.4% and 75.8%；

＜0.05）. At 1 and 3 months post-treatment， the serum levels of tumor markers decreased significantly from baseline in both groups， with significantly lower levels in the observation group than in the control group （

＜0.05）. No statistically significant differences were observed in the overall incidence of adverse events or the incidence of grade≥3 adverse events between the two groups （

＞0.05）. The median PFS was 10.6 months in the control group and 14.3 months in the observation group， with no statistically significan

t difference [hazard ratio （HR） of 0.69， 95% confidence interval （CI） of 0.44-1.09，

＝0.111

]

. During follow-up， 8 and 9 patients died in the control and observation groups， respectively， and the median OS was not reached in either group. The 12-month OS rates were 88.8% and 87.3%， respectively， with no statistically significant difference （HR of 0.88， 95%CI of 0.35-2.24，

＝0.790）. After adjustment for potential confounding factors in the original cohort， the ORR at 3 months post-treatment remained significantly higher in the observation group than in the control group （adjusted odds ratio of 2.67， 95%CI of 1.28-5.56，

＝0.009）. Additionally， the interaction between treatment modality and Barcelona Clinic Liver Cancer staging had no statistically significant impact on the ORR at 3 months post-treatment （

＝0.391）.

CONCLUSIONS

For patients with unresectable HCC， compared with conventional iodized oil emulsion-based TACE， small-caliber PVA microsphere-based TACE demonstrates superior efficacy in terms of early radiological response and improvement in tumor markers， and the two regimens are comparable in terms of safety.

关键词

Keywords

references

Tan E Y ， Danpanichkul P ， Yong J N ， et al . Liver cancer in 2021：global burden of disease study [J ] . J Hepatol ， 2025 ， 82 （ 5 ）： 851 - 860 .

Yilma M ， Houhong Xu R ， Saxena V ， et al . Survival outcomes among patients with hepatocellular carcinoma in a large integrated US health system [J ] . JAMA Netw Open ， 2024 ， 7 （ 9 ）： e2435066 .

Lanza C ， Ascenti V ， Amato G V ， et al . All you need to know about TACE：a comprehensive review of indications，techniques，efficacy，limits，and technical advancement [J ] . JCM ， 2025 ， 14 （ 2 ）： 314 .

Jin K ， Zeng S Y ， Li B ， et al . Bicarbonate-integrated transarterial chemoembolization （TACE） in real-world hepatocellular carcinoma [J ] . Sig Transduct Target Ther ， 2025 ， 10 （ 1 ）： 281 .

Jipa A M ， Makary M S . Locoregional therapies for hepatobiliary tumors：contemporary strategies and novel applications [J ] . Cancers ， 2024 ， 16 （ 7 ）： 1271 .

国家卫生健康委员会医政司 . 原发性肝癌诊疗指南：2024年版 [J ] . 中华外科杂志， 2024 ， 62 （ 6 ）： 477 - 503 .

Lu X ， Liu Q F ， Yan G ， et al . Engineering polyvinyl alcohol microspheres with capability for use in photothermal/chemodynamic therapy for enhanced transarterial chemoembolization [J ] . J Mater Chem B ， 2024 ， 12 （ 21 ）： 5207 - 5219 .

Lee B C ， Kim G M ， Park J ， et al . Comparison of chemoembolization outcomes using 70-150 µm and 100-300 µm drug-eluting beads in treating small hepatocellular carcinoma：a Korean multicenter study [J ] . Korean J Radiol ， 2024 ， 25 （ 8 ）： 715 - 725 .

Mohammadzadeh V ， Atapour-Mashhad H ， Shahvali S ， et al . Hydrogels as advanced drug delivery platforms for cancer immunotherapy：promising innovations and future outlook [J ] . J Nanobiotechnol ， 2025 ， 23 （ 1 ）： 545 .

Richter G ， Radeleff B ， Stroszczynski C ， et al . Safety and feasibility of chemoembolization with doxorubicin-loaded small calibrated microspheres in patients with hepatocel-lular carcinoma：results of the MIRACLE Ⅰ prospective multicenter study [J ] . Cardiovasc Intervent Radiol ， 2018 ， 41 （ 4 ）： 587 - 593 .

Cho Y ， Choi J W ， Kwon H ， et al . Transarterial chemoembolization for hepatocellular carcinoma：2023 expert consensus-based practical recommendations of the Korean Liver Cancer Association [J ] . J Liver Cancer ， 2023 ， 23 （ 2 ）： 241 - 261 .

Wei M ， Zhang P W ， Yang C F ， et al . 5-Fluorouracil combined with CalliSphere drug-eluting beads or conventional transarterial chemoembolization for unresectable hepatocellular carcinoma：a propensity score weighting analysis [J ] . Sci Rep ， 2024 ， 14 ： 25588 .

Eisenhauer E A ， Therasse P ， Bogaerts J ， et al . New response evaluation criteria in solid tumours：revised RECIST guideline：version 1.1 [J ] . Eur J Cancer ， 2009 ， 45 （ 2 ）： 228 - 247 .

U.S. Department of Health and Human Services . Common terminology criteria for adverse events （CTCAE） version 5.0 [EB/OL ] . [ 2026-05-15 ] . https：//www.ctc.ucl.ac.uk/TrialDocuments/Uploaded/Common%20Terminology%20Cr-iteria%20for%20Adverse%20Events%20（CTCAE）%20v5.0_14092023_0.pdf https://www.ctc.ucl.ac.uk/TrialDocuments/Uploaded/Common%20Terminology%20Cr-iteria%20for%20Adverse%20Events%20(CTCAE)%20v5.0_14092023_0.pdf .

Austin P C . Optimal caliper widths for propensity-score matching when estimating differences in means and dif-ferences in proportions in observational studies [J ] . Pharm Stat ， 2011 ， 10 （ 2 ）： 150 - 161 .

Mazza S ， Frigerio C ， Alfieri D ， et al . Prognostic role of basal serum alpha-fetoprotein in patients with hepatocel-lular carcinoma suitable for curative treatment [J ] . Medicina （Kaunas）， 2024 ， 60 （ 5 ）： 692 .

刘连新，张维志 . 肝细胞癌的微创治疗策略 [J ] . 中华消化外科杂志， 2024 ， 23 （ 4 ）： 548 - 553 .

中华预防医学会肝胆胰疾病预防与控制专业委员会，中国医疗保健国际交流促进会肝脏肿瘤学分会 . 精准制导技术应用于肝脏肿瘤诊断与治疗中国专家共识： 2024版 [J ] . 中华消化外科杂志， 2024 ， 23 （ 4 ）： 514 - 526 .

宣志明，姚雪松，宋鹏，等 . 小粒径载药微球经导管动脉化疗栓塞术治疗不可切除肝内胆管癌患者的疗效和安全性分析 [J/OL ] . 肝癌电子杂志， 2025 ， 12 （ 4 ）： 8 - 13 . https：//kns.cnki.net/reader/xmlinvoice=t4saLlX0LRvtrQ-JYSUs1pStJLD6WUJUsgS5%2BO6OQOrVOig4EjgD1P-RmLZ6IqG8SXUPvkD%2BwKhfQtRO2KSxcOlhJs0zxL-DVphyCopsgQxrLyTyWeGnHIgHguZ9HniT9ocRX%2Bl-CMlClJzgs9Vug47h4iPzVUyRtdcaVRuU%2BrO8kqQ%3D&platform=NZKPT&sourcetype=nxgp&product=CJF-Q&filename=GADZ202504003&tablename=cjfdlast2026& type=JOURNAL&scope=readonline&cflag=html&dflag=xml&pages=&language=CHS&trial=&nonce=78EE782-D2ED24C9A87FFEB58EAFD2147&loginType=trialRead https://kns.cnki.net/reader/xmlinvoice=t4saLlX0LRvtrQ-JYSUs1pStJLD6WUJUsgS5%2BO6OQOrVOig4EjgD1P-RmLZ6IqG8SXUPvkD%2BwKhfQtRO2KSxcOlhJs0zxL-DVphyCopsgQxrLyTyWeGnHIgHguZ9HniT9ocRX%2Bl-CMlClJzgs9Vug47h4iPzVUyRtdcaVRuU%2BrO8kqQ%3D&platform=NZKPT&sourcetype=nxgp&product=CJF-Q&filename=GADZ202504003&tablename=cjfdlast2026&type=JOURNAL&scope=readonline&cflag=html&dflag=xml&pages=&language=CHS&trial=&nonce=78EE782-D2ED24C9A87FFEB58EAFD2147&loginType=trialRead .

Prajapati H J ， Xing M Z ， Spivey J R ， et al . Survival，ef-ficacy，and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC [J ] . AJR Am J Roentgenol ， 2014 ， 203 （ 6 ）： W706 - W714 .

Zhang J ， Feng G A ， Li Y L ， et al . Drug-eluting bead transarterial chemoembolization with medium-sized versus small-sized CalliSpheres microspheres in unresectable primary liver cancer [J ] . Asia Pac J Clin Oncol ， 2022 ， 18 （ 4 ）： 388 - 393 .

Liu H K ， Fan W Z ， Li H Q ， et al . Idarubicin versus epirubicin in transarterial chemoembolization for Barcelona clinic liver cancer stage B hepatocellular carcinoma：an open-label，randomized，phase Ⅳ trial [J ] . Radiology ， 2025 ， 315 （ 2 ）： e242315 .

槐聪颖，张鑫鑫，崔玉秀 . 血清AFP、APRI及GGT/ALT检测对原发性肝癌经动脉化疗栓塞患者预后的预测价值 [J ] . 分子诊断与治疗杂志， 2025 ， 17 （ 1 ）： 132 - 136 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Characteristics and safety analysis of finerenone use in hospitalized patients with acute heart failure

Efficacy of finerenone combined with Shenkangning capsules in diabetic kidney disease patients with spleen-kidney yang deficiency and blood stasis syndrome

Efficacy and safety of different classes of antibacterial agents for hospitalized adult patients with community-acquired pneumonia： a network meta-analysis

Clinical observation of sacituzumab tirumotecan combined with bevacizumab in the treatment of HER2-negative breast cancer with brain metastases

Clinical research on the combination therapy of vericiguat and metoprolol in the treatment of heart failure with reduced ejection fraction

Related Author

SHU Bing

WANG Qi

FANG Yuting

YIN Tong

CHEN Kangyu

TANG Liqin

WANG Yangyang

ZHANG Yaqi

Related Institution

Dept. of Cardiovascular Medicine， The First Affiliated Hospital of University of Science and Technology of China （Anhui Provincial Hospital）

Dept. of Pharmacy， The First Affiliated Hospital of University of Science and Technology of China （Anhui Provincial Hospital）

Dept. of Nephrology，Changzhou Wujin Hospital of Traditional Chinese Medicine （Wujin Affiliated Hospital of Nanjing University of Chinese Medicine）

Dept. of Endocrinology，Changzhou Wujin Hospital of Traditional Chinese Medicine（Wujin Affiliated Hospital of Nanjing University of Chinese Medicine）

Dept. of Pharmacy， Beijing Hospital， National Center of Gerontology/National Clinical Research Center for Gerontology/The Key Laboratory of Geriatrics of NHC/Institute of Geriatric Medicine， Chinese Academy of Medical Sciences

⁰